What Courage Therapeutics does

Courage Therapeutics is a Newton, Massachusetts-based clinical-stage biopharmaceutical company founded in 2019 to develop precision therapeutics for genetic obesities, with a particular focus on melanocortin-4 receptor haploinsufficiency (MC4R HI). The company was co-founded by Dr. Roger Cone, a pioneering researcher in melanocortin receptor biology who is credited with developing the first drug for syndromic obesity (Imcivree, FDA-approved in 2020) and is a member of both the National Academy of Sciences and the National Academy of Medicine. Its lead candidate, CTX-B, is a weekly injectable MC4R agonist designed to restore pathway activity and reduce hyperphagia in patients with MC4R HI, a well-defined genetic obesity affecting an estimated 100,000–150,000 patients in the United States with no currently approved targeted therapeutic. The underlying platform technology uses agonists that act directly on MC4R or augment endogenous ligand levels to compensate for defects in the leptin–POMC–MC4R signaling axis, and preclinical data in non-human primates show no cardiovascular signal at supratherapeutic exposures — addressing a historical liability that caused suspension of prior MC4R programs.

The company is pre-revenue and operates in the preclinical/IND-enabling stage, with go-to-market contingent on regulatory approval and subsequent distribution through established pharmaceutical wholesale and specialty pharmacy channels targeting academic medical centers and specialty obesity/endocrinology clinics. Revenue, when generated, is expected to come from pharmaceutical product sales (and potentially one-time licensing transactions), with pricing not yet established. As of November 2025, the company had raised over $11 million in seed financing led by Arsenal Bridge Ventures, with Isaac Barchas (Arsenal Bridge Ventures Managing Director) serving on the Board; total identified funding to date is approximately $12 million across the 2021 and 2025 rounds. Courage is led by CEO Giovanni Ferrara (formerly President and CEO of Medeor Therapeutics and founder/CEO of NeuroVia), with Tomi Sawyer as Chief Medicinal Chemist (inventor of Iclusig, Scenesse, and ALRN-6924), Sasha Blaug as CBO-CFO (former SVP at Biomea Fusion), and George Grass as Head of Non-Clinical.

The business model is currently focused on translating academic MC4R research into a single IND-ready asset and expanding the CTX platform into adjacent therapeutic areas within the broader MC4R pathway population (250,000+ US patients with severe obesity from MC4R mutations), with stated interest in obesity and wasting diseases more broadly. Customer segments are not yet defined by sales but by target patient populations — primarily MC4R HI patients with early-onset hyperphagia and severe obesity. Distribution upon approval is expected to flow through specialty channels, and commercial engagement today is conducted via scientific conferences and direct outreach to the medical and scientific community rather than traditional marketing channels.

Name

Courage Therapeutics

Legal name

Courage Therapeutics

Website

https://couragetx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Courage Therapeutics is a Newton, Massachusetts-based preclinical biopharmaceutical company developing CTX-B, a weekly injectable MC4R agonist targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a genetic obesity affecting 100,000–150,000 US patients with no approved targeted therapy.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Obesity Medicine & Weight Management (HLAKADAL)

Keywords

• Genetic obesity therapeutics
• MC4R receptor agonists
• Rare disease treatment
• Metabolic disorder drugs
• Precision neuroendocrinology

Headquarters

HQ city

Newton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue biopharmaceutical company developing CTX-B and potentially other MC4R pathway-targeted therapeutics. Expected to generate revenue through pharmaceutical product sales upon regulatory approval.

Distribution channels1 record

Marketing channels1 record

Core offering

Courage Therapeutics is a preclinical-stage neuroendocrine biopharmaceutical company developing precision therapeutics for genetic obesities. Its lead candidate, CTX-B, is a weekly injectable MC4R (melanocortin-4 receptor) agonist designed to treat melanocortin-4 receptor haploinsufficiency (MC4R HI), a well-defined genetic obesity characterized by early onset hyperphagia and severe obesity with no approved targeted therapeutic options, affecting an estimated 100,000-150,000 patients in the United States.

Product overview

Courage Therapeutics is a neuroendocrine company developing precision therapeutics for genetic obesities. The company's primary product candidate is CTX-B, a weekly injectable MC4R agonist designed to treat melanocortin-4 receptor haploinsufficiency (MC4R HI). The company is also developing the CTX platform for extension into additional therapeutic areas within the MC4R pathway.

Differentiator

Problem solved

Functional benefit

Products and services

• CTX-B

Quantifiable outcome

• Significant weight loss in preclinical MC4R HI models
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Soleno Therapeutics: Clinical-stage rare-disease company developing therapeutics for hyperphagia-driven obesities (e.g., Prader-Willi syndrome) using a different mechanism (Diazoxide Choline Extended-Release). Comparable as a small-cap rare genetic obesity specialist targeting hyperphagia and severe obesity, similar patient archetype to MC4R HI.
• Rhythm Pharmaceuticals: Commercial-stage biopharma developing setmelanotide (Imcivree), the FDA-approved MC4R agonist for several rare genetic obesities including MC4R pathway-related indications. The most directly comparable peer: Courage is pursuing an adjacent MC4R-targeted indication with CTX-B, leveraging the same validated pathway.

Emerging players

• Viking Therapeutics: Clinical-stage metabolic-disease company with an obesity pipeline (e.g., VK2735 oral/injectable GLP-1/GIP). Comparable as a small-cap biotech pursuing differentiated obesity therapeutics in a landscape reshaped by GLP-1 incumbents.
• Aardvark Therapeutics: Clinical-stage company developing therapies for hyperphagic disorders including Prader-Willi syndrome, overlapping with Courage's focus on hyperphagia-driven genetic obesity but with a different mechanism (oral bitter taste receptor agonist). Comparable as a competitor pursuing similar orphan hyperphagia indications.
• Clinuvel Pharmaceuticals: Commercial-stage company that developed Scenesse (afamelanotide), an MC1R agonist invented by Courage's Chief Medicinal Chemist Tomi Sawyer. Comparable as a melanocortin-receptor-targeted specialty biopharma with regulatory and commercial expertise in the melanocortin pathway.
• Structure Therapeutics: Clinical-stage company developing oral small-molecule GLP-1 agonists for obesity and related metabolic diseases. Comparable as a small-cap biotech pursuing next-generation obesity therapeutics outside the incumbent peptide GLP-1 framework.

Others

• Aileron Therapeutics: Clinical-stage oncology biopharma where Courage's Chief Medicinal Chemist Tomi Sawyer previously served as CSO and co-invented ALRN-6924. Relevant as a talent-network peer through which Courage's leadership has prior drug-discovery and development experience.
• Novo Nordisk:
• Medeor Therapeutics: Clinical-stage transplant immunology company previously led by Courage's CEO Giovanni Ferrara, who completed the first Phase 3 transplant immunotolerance study there. Relevant as a prior-leadership comparable rather than a product competitor.

Broad incumbents

• Eli Lilly: Large pharmaceutical company with Zepbound (tirzepatide) and broader obesity/metabolic pipeline. Relevant as the dominant incumbent shaping the obesity treatment landscape against which any new obesity therapeutic, including CTX-B, must compete for prescriber attention and payer coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Courage Therapeutics